Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with Aojing Medical (688613.SH) leading the "degradable semi-hydrated calcium sulfate" project [1][2]. Industry Overview - Biomedical materials are referred to as the "chip of medical devices" and are crucial for the localization of high-end medical equipment. However, China faces significant challenges in the fields of degradable bone repair materials and magnesium alloys, with over 60% of the high-end bone repair materials market being occupied by imported products [1][2]. - The current market for bone repair materials is dominated by foreign companies that monopolize core technologies, leading to high prices and clinical standard dominance, which exacerbates accessibility issues for domestic patients [1]. Company Positioning - Aojing Medical is recognized as a leading enterprise in the field of mineralized collagen bone repair materials, with a strong commitment to long-term R&D investment and a multidisciplinary research team [2][3]. - The company has accumulated substantial technical reserves in key areas such as high-end regenerative medical materials and advanced manufacturing processes, and has undertaken numerous national and provincial major R&D projects [2]. Strategic Importance - The successful selection in the "revealing the list" initiative signifies national endorsement of Aojing Medical's technological route and R&D capabilities, positioning the company as a leader in the domestic high-end bone repair materials sector [3][4]. - Aojing Medical aims to collaborate with universities and hospitals to tackle key technical challenges, conduct multi-center clinical trials, and establish clinical standards, thereby shortening product launch cycles and enhancing the overall value of China's biomedical materials industry [3]. Market Potential - The market for bone repair materials in China is projected to exceed 35 billion yuan by 2030, with a domestic production rate expected to surpass 70%. The share of degradable materials is anticipated to increase from 15% to 40% [3].

Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with Aojing Medical (688613.SH) leading the "degradable semi-hydrated calcium sulfate" project team, highlighting the company's role in addressing the domestic challenges in high-end bone repair materials [1][2]. Industry Overview - Biomedical materials are referred to as the "chips of medical devices" and are crucial for the localization of high-end medical equipment. Currently, over 60% of the high-end bone repair materials market in China is dominated by imported products, leading to high costs and clinical standard monopolization by foreign companies [1][2]. - The degradable semi-hydrated calcium sulfate is a revolutionary material in bone defect repair, offering advantages such as good biocompatibility, self-curing properties, and adaptability to complex bone defects. However, the core technical challenge lies in maintaining a dynamic balance between degradation and bone regeneration [1][3]. Company Insights - Aojing Medical is recognized as a leading enterprise in the field of mineralized collagen bone repair materials, with a strong commitment to long-term R&D investment and a multidisciplinary research team. The company has accumulated significant technical reserves in key areas such as high-end regenerative medical materials and advanced manufacturing processes [2][3]. - The successful selection in the "revealing the list" initiative signifies Aojing Medical's leadership in the domestic high-end bone repair materials sector. The company aims to collaborate with universities and hospitals to tackle key technical challenges and streamline clinical standard development, thereby enhancing its integrated industry chain from material research to clinical application [3][4]. Market Potential - Under the guidance of the "Healthy China 2030" strategy, the biomedical materials industry is entering a golden development period. According to Frost & Sullivan, the market size for bone repair materials in China is expected to exceed 35 billion yuan by 2030, with the localization rate likely surpassing 70%. The proportion of degradable materials is projected to increase from the current 15% to 40% [3].

Core Viewpoint - The article discusses the announcement of the second batch of selected units for the "Innovation Task of Biomedical Materials" by the Ministry of Industry and Information Technology, highlighting various innovative materials and their respective companies involved in their development [2][3]. Group 1: Polymer Materials - Key materials include Polyethylene Terephthalate, Phosphorylcholine-based Polymers, High Purity Acrylic Monomers, and High Oxygen Permeability Silicones [3][4]. - Companies involved in these materials include China Petrochemical Corporation, Weigao Group, and Jiangsu New Vision Advanced Functional Fiber Innovation Center [4][5]. - Other notable materials are Dendritic Light-sensitive Smart Materials and Anti-thrombus New Materials, with companies like Jiangsu Baisei Biotechnology and BoHui (Zhejiang) Biotechnology [3][6]. Group 2: Metal Materials - Key materials in this category include Ultra-fine Crystal Titanium Rod Wire, Porous Tantalum, Zirconium Niobium Alloys, and High-end Stainless Steel Wire [7][8]. - Companies such as Baoji Xinnuo Special Materials and Shenzhen Shigesaisi Medical Technology are involved in the production of these materials [9]. Group 3: Inorganic Non-metallic Materials - Important materials include Degradable Semi-hydrated Calcium Sulfate, Silicon Nitride Ceramics, and 3D Printing Zirconia Ceramic Inks [10][11]. - Companies like Zhongding Kairui Technology and Beijing Bansai Technology are engaged in the development of these materials [11].

Group 1 - The core viewpoint of the news is that Aojing Medical's stock performance and financing activities indicate a low level of investor confidence, with a net financing buy of -58.05 million yuan on August 26 [1] - As of August 26, Aojing Medical's total financing and securities balance is 128 million yuan, which is 4.52% of its market capitalization, indicating a low financing level compared to the past year [1] - The company has not engaged in any short selling activities on August 26, with a short selling balance of 0, suggesting a lack of bearish sentiment among investors [1] Group 2 - As of March 31, Aojing Medical had 7,905 shareholders, a decrease of 2.85% from the previous period, while the average number of circulating shares per shareholder increased by 2.93% to 17,147 shares [2] - For the first quarter of 2025, Aojing Medical reported a revenue of 42.46 million yuan, a year-on-year decrease of 10.35%, and a net profit attributable to shareholders of 1.04 million yuan, down 84.99% year-on-year [2] - The company has distributed a total of 58.67 million yuan in dividends since its A-share listing, with 22.40 million yuan distributed over the past three years [3]

天眼查商业履历信息显示，奥精医疗科技股份有限公司，成立于2004年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本13555.1584万人民币，实缴资本13555.1584万人民币。公司法定代 表人为胡刚。 通过天眼查大数据分析，奥精医疗科技股份有限公司共对外投资了8家企业，参与招投标项目131次，知 识产权方面有商标信息48条，专利信息134条，此外企业还拥有行政许可21个。 来源：金融界 金融界消息 截至2025年8月25日收盘，奥精医疗（688613）报收于20.68元，下跌1.15%，换手率 3.59%，成交量4.92万手，成交金额1.03亿元。 资金流向方面，今日主力资金净流出1133.35万元，占比成交额11.05%。其中，超大单净流出610.54万 元、占成交额5.95%，大单净流出522.81万元、占成交额5.1%，中单净流出流入523.69万元、占成交额 5.11%，小单净流入609.66万元、占成交额5.94%。 奥精医疗最新一期业绩显示，截至2025一季报，公司营业总收入4245.97万元、同比减少10.35%，归属 净利润104.15万元，同比减少84.99%，扣非净利润 ...

Group 1 - The core point of the news is that AoJing Medical has seen a financing buy-in amount of 0.12 billion yuan on August 22, ranking 1432nd in the two markets, with a net sell of 798,600 yuan on the same day [1] - Over the last three trading days from August 20 to August 22, AoJing Medical received financing buy-ins of 0.11 billion yuan, 0.10 billion yuan, and 0.12 billion yuan respectively [1] Group 2 - In terms of securities lending, there were no shares sold or net sold on the same day [2]

Core Points - The company has temporarily used idle raised funds amounting to RMB 30 million for supplementing its working capital, ensuring that it does not affect the progress of the investment projects [1] - The board and supervisory committee have approved the use of these funds, and the sponsor institution has provided verification opinions [1] - As of August 19, 2025, the company has fully returned the temporarily used idle funds of RMB 29,238,079.34 to the designated account [2]

Company Overview - Aojing Medical focuses on the research, production, and sales of high-end medical devices, with main products including artificial bone repair materials and other Class III medical devices [1] - As of August 19, 2025, Aojing Medical's stock price was 21.55 yuan, down 0.51 yuan or 2.31% from the previous trading day [1] Financial Performance - On August 19, the trading volume was 50,382 hands, with a total transaction amount of 110 million yuan [1] - The company announced the return of 29.2381 million yuan of idle raised funds to the designated account, which was initially planned for temporary liquidity support with a usage period of 12 months, but was used for less than a year [1] Capital Flow - On August 19, the net inflow of main funds was 4.0475 million yuan, accounting for 0.14% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 5.2782 million yuan, representing 0.18% of the circulating market value [1]

Group 1 - The company announced the convening of the 11th meeting of the 2nd Board of Directors and the 11th meeting of the 2nd Supervisory Board on August 26, 2024 [1] - The meetings approved the proposal to temporarily use part of the idle raised funds to supplement working capital, with a maximum amount of RMB 30 million [1] - The usage period for the idle raised funds is within 12 months from the date of the Board's approval [1] Group 2 - As of August 19, 2025, the company has fully returned the temporarily used idle raised funds amounting to RMB 29,238,079.34 to the special account for raised funds [1] - The company has notified its sponsor institution and the sponsor representative about the return of the raised funds [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码： 688613 证券简称：奥精医疗 公告编号： 2025-040 特此公告。 奥精医疗科技股份有限公司董事会 2025年8月20日 1 奥精医疗科技股份有限公司（以下简称"公司"）于2024年8月26日分别 召开了第二届董事会第十一次会议、第二届监事会第十一次会议，会议审议通 过了《关于公司使用部分闲置募集资金暂时补充流动资金的议案》，同意公司 在确保不影响募集资金投资项目建设进度的前提下，使用闲置募集资金不超过 人民币3,000.00万元暂时用于补充公司流动资金，使用期限为自公司董事会审 议通过之日起12个月内。监事会对上述议案发表了明确的同意意见，保荐机构 对上述事项发表了核查意见。具体内容详见公司于2024年8月27日在上海证券交 易所官网（www.sse.com.cn）披露的《奥精医疗科技股份有限公司关于公司使 用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2024-034）。 根据董事会决议，公司在规定期限内使用29,238,079.34元闲置募集 ...